Oncolytics Biotech Inc (ONCY) · Oct 14, 2026 · Other events
Cohort 4 data pending — Median overall survival exceeds expectations; final results due Q4 2026
Oncolytics’ clinical update points to better-than-expected anal-cancer survival, but leaves pancreatic data timing and magnitude unresolved.
The company is shifting from exploratory GOBLET work toward registration-focused anal and colorectal cancer programs. Earlier in 2026, Oncolytics said GOBLET enrollment was complete and that capital would be redirected toward registration and registration-enabling studies, making the remaining cohorts primarily a source of confirmatory data rather than the company’s main development engine.
The anal-cancer signal is encouraging, but this is not yet a clinical readout. Management says median overall survival in Cohort 4 exceeds expectations, while final results are now expected in the fourth quarter of 2026. That is directionally better than a routine follow-up update, but without the actual median, response data, or a full dataset, it does not establish that the study cleared a new efficacy bar.
The pancreatic program remains slower and less decisive. Initial Cohort 5 results are now expected in the first half of 2027 and could take longer because patients remain on treatment and follow-up. The company is also winding down the broader GOBLET infrastructure, so this study is moving into a data-maturation phase rather than generating near-term expansion of the pipeline.
Bottom line: This update modestly improves confidence in the anal-cancer signal but provides no hard efficacy numbers and pushes the pancreatic evidence further out. It matters mainly as a timing and confirmation update, not as a fresh proof point for pelareorep.
Final Cohort 4 results, Q4 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!